Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hypertension

Free Subscription Articles published in J Cardiovasc Pharmacol Retrieve available abstracts of 33 articles: HTML format

Single Articles

October 2022
1. KANG L, Liu X, Li Z, Li X, et al
   Sildenafil improves pulmonary vascular remodeling in a rat model of persistent pulmonary hypertension of the newborn.
   J Cardiovasc Pharmacol. 2022 Oct 1. pii: 00005344-990000000-00118.
   PubMed     Abstract available
   
   
   
2. GUHA A, Gong Y, DeRemer D, Owusu-Guha J, et al
   Cardiometabolic Consequences of Targeted Anticancer Therapies.
   J Cardiovasc Pharmacol. 2022;80:515-521.
   PubMed     Abstract available
   
   
   September 2022
3. SWAMI VETHA BS, Byrum R, Peele K, Diz D, et al
   Functional Significance of Angiotensin Receptor Type 2 in the Neuroplasticity of Autonomic Ganglia in (mRen2)27 Transgenic Hypertensive Rats.
   J Cardiovasc Pharmacol. 2022 Sep 16. pii: 00005344-990000000-00116.
   PubMed     Abstract available
   
   
   
4. 
   Sacubitril/Valsartan Improves Sexual Function and Fibrosis of the Clitoral and Vaginal Tissues in Female Spontaneously Hypertensive Rats: Erratum.
   J Cardiovasc Pharmacol. 2022;80:489.
   PubMed    
   
   
   August 2022
5. CHUQUIN D, Abbate A, Bottinor W
   Hypertension in Cancer Survivors: A Review of the Literature and Suggested Approach to Diagnosis and Treatment.
   J Cardiovasc Pharmacol. 2022 Aug 25. pii: 00005344-990000000-00110.
   PubMed     Abstract available
   
   
   
6. YANG S, Shen W, Zhang HZ, Wang CX, et al
   Efficacy and Safety of Finerenone for Prevention of Cardiovascular Events in Type 2 Diabetes Mellitus with Chronic Kidney Disease: A Meta-analysis of Randomized Controlled Trials.
   J Cardiovasc Pharmacol. 2022 Aug 23. pii: 00005344-990000000-00107.
   PubMed     Abstract available
   
   
   
7. D'SOUZA MS, Luu AN, Guisinger TC, Seeley SL, et al
   Regulator of G-Protein Signaling 5 Protein Deficiency Differentially Influences Blood Pressure, Vascular and Behavioral Effects in Aged Male Mice.
   J Cardiovasc Pharmacol. 2022;80:305-313.
   PubMed     Abstract available
   
   
   July 2022
8. IMAM SS, El-Farrash RA, Taha AS, Saleh GA, et al
   Milrinone Versus Sildenafil in Treatment of Neonatal Persistent Pulmonary Hypertension: A Randomized Control Trial.
   J Cardiovasc Pharmacol. 2022 Jul 12. pii: 00005344-990000000-00081.
   PubMed     Abstract available
   
   
   May 2022
9. CAI H, Fan S, Cai L, Zhu L, et al
   Dihydroartemisinin attenuates hypoxia-induced pulmonary hypertension through the ELAVL2/miR-503/PI3K/AKT axis.
   J Cardiovasc Pharmacol. 2022 May 5. pii: 00005344-990000000-00028.
   PubMed     Abstract available
   
   
   April 2022
10. CHENG L, Maboh RN, Wang H, Mao GW, et al
    Naoxintong capsule activates the Nrf2/HO-1 signaling pathway and suppresses the p38alpha signaling pathway via estrogen receptors to ameliorate heart remodeling in female mice with postmenopausal hypertension.
    J Cardiovasc Pharmacol. 2022 Apr 29. pii: 00005344-990000000-00034.
    PubMed     Abstract available
    
    
    
11. BAO M, Song Y, Wu S, Li J, et al
    The influence of hypersensitive C-reactive protein on the effect of continuous antihypertensive pharmacological therapy.
    J Cardiovasc Pharmacol. 2022 Apr 5. pii: 00005344-990000000-00017.
    PubMed     Abstract available
    
    
    
12. CHAN TH, Tsoi MF, Yung Cheung BM
    Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study.
    J Cardiovasc Pharmacol. 2022;79:577-582.
    PubMed     Abstract available
    
    
    March 2022
13. ZHUANG C, Yi G, Wang W, Sun R, et al
    Sacubitril/Valsartan Improves Sexual Function and Fibrosis of the Clitoral and Vaginal Tissues in Female Spontaneously Hypertensive Rats.
    J Cardiovasc Pharmacol. 2022 Mar 8. pii: 00005344-990000000-00003.
    PubMed     Abstract available
    
    
    
14. JOB R, Abdul Qader M, Torres P, Al Abbasi B, et al
    Renin-Angiotensin System Blocker in COVID-19. A Single Center Study.
    J Cardiovasc Pharmacol. 2022;79:311-314.
    PubMed     Abstract available
    
    
    
15. HAN H, Dou J, Hou Q, Wang H, et al
    Role of Circadian Rhythm and Impact of Circadian Rhythm Disturbance on the Metabolism and Disease.
    J Cardiovasc Pharmacol. 2022;79:254-263.
    PubMed     Abstract available
    
    
    November 2021
16. TEMIZ-RESITOGLU M, Guden DS, Senol SP, Vezir O, et al
    Pharmacological inhibition of mTOR attenuates DOCA-salt-induced hypertension and related pathophysiology: regulation of oxidative stress, inflammation and cardiovascular hypertrophy in male rats.
    J Cardiovasc Pharmacol. 2021 Nov 23. pii: 00005344-900000000-98105.
    PubMed     Abstract available
    
    
    October 2021
17. ALVES QL, Vieira da Silva Santos P, Santos WA, Dantas Damasceno SC, et al
    Unraveling the cardiac effects induced by carvacrol in spontaneously hypertensive rats: Involvement of TRPM4 and TRPM7 channels.
    J Cardiovasc Pharmacol. 2021 Oct 28. pii: 00005344-900000000-98123.
    PubMed     Abstract available
    
    
    
18. ZHU T, Wang X, Zheng Z, Quan J, et al
    ZIP12 Contributes to Hypoxic Pulmonary Hypertension by Driving Phenotypic Switching of Pulmonary Artery Smooth Muscle Cells.
    J Cardiovasc Pharmacol. 2021 Oct 21. pii: 00005344-900000000-98129.
    PubMed     Abstract available
    
    
    
19. ABDELMONEM M, Ebada MA, Diab S, Ahmed MM, et al
    Efficacy of Hibiscus Sabdariffa on Reducing Blood Pressure in Patients with Mild to Moderate Hypertension: A Systematic Review and Meta-Analysis of published randomized controlled trials.
    J Cardiovasc Pharmacol. 2021 Oct 20. pii: 00005344-900000000-98127.
    PubMed     Abstract available
    
    
    
20. ADIE SK, Abdul-Aziz AA, Ketcham SW, Moles VM, et al
    Considerations for inotrope and vasopressor use in critically ill patients with pulmonary arterial hypertension.
    J Cardiovasc Pharmacol. 2021 Oct 6. pii: 00005344-900000000-98139.
    PubMed     Abstract available
    
    
    August 2021
21. LUO S, Kan J, Zhang J, Ye P, et al
    Bioactive Compounds From Coptidis Rhizoma Alleviate Pulmonary Arterial Hypertension by Inhibiting Pulmonary Artery Smooth Muscle Cells' Proliferation and Migration.
    J Cardiovasc Pharmacol. 2021;78:253-262.
    PubMed     Abstract available
    
    
    July 2021
22. PENG M, He J, Xue Y, Yang X, et al
    The role of hypertension on the severity of COVID-19: a review.
    J Cardiovasc Pharmacol. 2021 Jul 22. pii: 00005344-900000000-98170.
    PubMed     Abstract available
    
    
    
23. KRYSIAK R, Basiak M, Okopien B
    Impact of lisinopril on cardiometabolic risk factors in men with hypertension and early-onset androgenetic alopecia: a pilot study.
    J Cardiovasc Pharmacol. 2021 Jul 20. pii: 00005344-900000000-98169.
    PubMed     Abstract available
    
    
    
24. WANG Y, Wang JW, Wang Y, Yang B, et al
    Monitoring Antihypertensive Medication Adherence by LC-MS/MS: Method Establishment and Clinical Application.
    J Cardiovasc Pharmacol. 2021 Jul 9. pii: 00005344-900000000-98173.
    PubMed     Abstract available
    
    
    June 2021
25. HAMMOUD S, Kurdi M, van den Bemt BJ
    Impact of Fasting on Cardiovascular Outcomes in Patients with Hypertension.
    J Cardiovasc Pharmacol. 2021 Jun 29. pii: 00005344-900000000-98181.
    PubMed     Abstract available
    
    
    
26. WATSON K, Kukin A, Wasik AK, Shulenberger CE, et al
    Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease.
    J Cardiovasc Pharmacol. 2021;77:685-698.
    PubMed     Abstract available
    
    
    May 2021
27. YANG S, Zhang H, Yang P, Wang C, et al
    Efficacy and Safety of LCZ696 for Short-term Management of Essential Hypertension Compared With ARBs: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021;77:650-659.
    PubMed     Abstract available
    
    
    
28. ZOUEIN FA, Altara R, Massoud GP, Booz GW, et al
    The Angiotensin II Type 1(AT1) Receptor and Cardiac Hypertrophy: Did We Have It Wrong All Along?
    J Cardiovasc Pharmacol. 2021;77:531-535.
    PubMed     Abstract available
    
    
    April 2021
29. MCCOY EK, Lisenby KM
    Aprocitentan (a dual endothelin receptor antagonist) for Treatment-Resistant Hypertension.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98239.
    PubMed     Abstract available
    
    
    
30. YAMAGATA K, Yamori Y
    Altered properties of neurons and astrocytes and the effects of food components in stroke-prone spontaneously hypertensive rats.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98237.
    PubMed     Abstract available
    
    
    
31. GILEWSKI W, Banach J, Rogowicz D, Wolowiec L, et al
    Treatment of hypertension due to immunosuppressive therapy after solid organ transplantation - pharmacological approach.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98236.
    PubMed     Abstract available
    
    
    
32. MIOTTO DS, Duchatsch F, Macedo AG, Ruiz TFR, et al
    Perindopril Reduces Arterial Pressure and Does Not Inhibit Exercise-Induced Angiogenesis in Spontaneously Hypertensive Rats.
    J Cardiovasc Pharmacol. 2021;77:519-528.
    PubMed     Abstract available
    
    
    March 2021
33. RAJABI S, Najafipour H, Farsangi SJ, Joukar S, et al
    Quercetin, Perillyl alcohol and Berberine ameliorate right ventricular disorders in experimental pulmonary arterial hypertension: Effects on miR-204, miR-27a, fibrotic, apoptotic and inflammatory factors.
    J Cardiovasc Pharmacol. 2021 Mar 12. pii: 00005344-900000000-98234.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hypertension is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: